Isavuconazonium Sulfate: a Novel Antifungal Agent
作者： Douglas Slain , John D. Cleary
DOI: 10.1007/S12281-015-0241-2
关键词:
摘要: Isavuconazonium sulfate is an orally or intravenously administered water-soluble prodrug that rapidly converts to the active triazole antifungal agent isavuconazole in systemic circulation. Isavuconazole has broad activity includes Candida, Aspergillus spp., and Mucorales. offers several advantages over previous broad-spectrum antifungals. The drug well-absorbed from oral capsule does not appear be significantly impacted by food intake alterations gastric acidity. intravenous formulation require use of a renally eliminated cyclodextrin carrier molecule. displays linear pharmacokinetics with low interpatient variability patients without hepatic insufficiency. drug’s long half-life allows for once-daily dosing (loading doses are utilized when treating serious infections). generally well-tolerated. Adverse effects experienced clinical trials included gastrointestinal effects, elevated enzymes, headache, hypokalemia. subject interactions, albeit at lower rate than other
springer.com
sci-hub.se 参考文章(57)
Dimitrios Kontoyiannis, Michael Giladi, Misun Lee, Marcio Nucci, Issam Raad, Eric Bow, Vicki a. Morrison, John Baddley, Bernhardt Zeiher, Rochelle Maher, Wenmei Huang, Kieren a. Marr, 1211A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients Open Forum Infectious Diseases. ,vol. 1, pp. S37- S37 ,(2014) , 10.1093/OFID/OFU051.99
M. R. Shivaprakash, Erik Geertsen, Arunaloke Chakrabarti, Johan W. Mouton, Jacques F. Meis, In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs Mycoses. ,vol. 54, pp. 583- 589 ,(2011) , 10.1111/J.1439-0507.2010.01996.X
OA Cornely, S Arikan‐Akdagli, E Dannaoui, AH Groll, Katrien Lagrou, A Chakrabarti, F Lanternier, LIVIO Pagano, A Skiada, M Akova, MC Arendrup, T Boekhout, A Chowdhary, M Cuenca‐Estrella, T Freiberger, J Guinea, J Guarro, S de Hoog, W Hope, E Johnson, S Kathuria, M Lackner, C Lass‐Flörl, O Lortholary, JF Meis, J Meletiadis, P Muñoz, M Richardson, E Roilides, AM Tortorano, AJ Ullmann, A van Diepeningen, P Verweij, G Petrikkos, None, ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013 Clinical Microbiology and Infection. ,vol. 20, pp. 5- 26 ,(2014) , 10.1111/1469-0691.12371
Hamid Badali, Seyed Amir Yazdanparast, Alexandro Bonifaz, Bita Mousavi, G. Sybren de Hoog, Corné H. W. Klaassen, Jacques F. Meis, Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility Mycopathologia. ,vol. 175, pp. 505- 513 ,(2013) , 10.1007/S11046-013-9631-6
Shivaprakash M. Rudramurthy, Arunaloke Chakrabarti, Erik Geertsen, Johan W. Mouton, Jacques F. Meis, In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing Diagnostic Microbiology and Infectious Disease. ,vol. 71, pp. 370- 377 ,(2011) , 10.1016/J.DIAGMICROBIO.2011.08.006
Paul L. McCormack, Isavuconazonium: First Global Approval Drugs. ,vol. 75, pp. 817- 822 ,(2015) , 10.1007/S40265-015-0398-6
Guanpingsheng Luo, Teclegiorgis Gebremariam, Hongkyu Lee, John E. Edwards, Laura Kovanda, Ashraf S. Ibrahim, Isavuconazole Therapy Protects Immunosuppressed Mice from Mucormycosis Antimicrobial Agents and Chemotherapy. ,vol. 58, pp. 2450- 2453 ,(2014) , 10.1128/AAC.02301-13
Anupam Prakash Anupam Prakash, Sandeep Wankhede Sandeep Wankhede, PK Singh, Kshitij Agarwal Kshitij Agarwal, Shallu Kathuria Shallu Kathuria, Sharmila Sengupta Sharmila Sengupta, Purabi Barman Purabi Barman, JF Meis, Anuradha Chowdhary Anuradha Chowdhary, None, First neonatal case of fungaemia due to Pseudozyma aphidis and a global literature review Mycoses. ,vol. 57, pp. 64- 68 ,(2014) , 10.1111/MYC.12098
Toshikazu Yamazaki, Yukiko Inagaki, Toshihiko Fujii, Jun Ohwada, Masao Tsukazaki, Isao Umeda, Kazuko Kobayashi, Nobuo Shimma, Malcolm G.P. Page, Mikio Arisawa, In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan International Journal of Antimicrobial Agents. ,vol. 36, pp. 324- 331 ,(2010) , 10.1016/J.IJANTIMICAG.2010.06.003
Haran T. Schlamm, Kieren A. Marr, Combination Therapy for Invasive Aspergillosis: Controversies and Conclusions Current Fungal Infection Reports. ,vol. 9, pp. 130- 134 ,(2015) , 10.1007/S12281-015-0220-7